Arrivent Biopharma Inc. (AVBP)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
AVBP Chart
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public offering of 2,482,692 shares of its common stock at a price to the public of $19.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,363,469 shares of its common stock at a price to the public of $19.4999, which represents the per share public offering price for the shares of common stock less $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to ArriVent from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $75 million. In addition, ArriVent has granted the underwriters a 30-day option to purchase up to an additional 576,923 shares of its common stock on the same terms and conditions. All of the securities are being offered by ArriVent.
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. In addition, ArriVent expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total amount of common stock and shares of common stock underlying pre-funded warrants on the same terms and conditions. All of the securities are being offered by ArriVent.
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the Company will host a virtual investor event to discuss the firmonertinib clinical program for the treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC) on June 23, 2025 at 8:00 am ET.
Arrivent Biopharma Inc. Dividends
Arrivent Biopharma Inc. Earnings
| 13 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 27 Mar 2025 Date | | - Cons. EPS | - EPS |
| 14 Nov 2024 Date | | - Cons. EPS | - EPS |
| 15 Aug 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 27 Mar 2025 Date | | - Cons. EPS | - EPS |
| 14 Nov 2024 Date | | - Cons. EPS | - EPS |
| 15 Aug 2024 Date | | - Cons. EPS | - EPS |
Arrivent Biopharma Inc. (AVBP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Arrivent Biopharma Inc. ever had a stock split?
Arrivent Biopharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Zhengbin Yao CEO | NASDAQ (NMS) Exchange | 04272N102 Cusip |
| US Country | 52 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical entity focused on addressing the critical unmet medical needs of cancer patients primarily in the United States. Founded in 2021 and situated in Newtown Square, Pennsylvania, the company is dedicated to the pursuit of novel medical solutions through the identification, development, and commercialization of therapeutic interventions for cancer. With a clear emphasis on bringing targeted cancer therapies to the market, especially for non-small cell lung cancer (NSCLC) and other solid tumors, ArriVent BioPharma underscores its role in the oncological landscape by tackling complex challenges in the current treatment paradigms. The company's robust development strategies and strategic alliances underscore its potential to make significant advancements in oncology therapeutics.
Products and Services
- Furmonertinib
A third-generation tyrosine kinase inhibitor, Furmonertinib is centrally involved in ArriVent BioPharma's clinical trials, targeting multiple epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC). The drug is currently undergoing a phase 3 clinical trial specifically designed for patients with metastatic EGFRm NSCLC. Additionally, Furmonertinib is in a phase 1b clinical trial for the treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations. The development of Furmonertinib, with its focus on a key aspect of NSCLC, highlights the company's commitment to pioneering in the area of targeted cancer therapy.
- ARR-002
ARR-002 represents another facet of ArriVent BioPharma's developmental pipeline, further emphasizing its dedication to expanding the range of treatment options available for cancer patients. While specific details on ARR-002 are more limited, its inclusion in the company's portfolio signifies its ongoing efforts in broadening its research and development activities to cover a wider spectrum of oncological needs.
- Strategic Collaborations
The company has established strategic partnerships to enhance its product development capabilities and commercial outreach. Notably, ArriVent BioPharma collaborates with Aarvik Therapeutics Inc. for the discovery and development of antibody drug conjugates (ADCs) that aim for improved activity and safety over single target bivalent ADCs. Another significant partnership with Shanghai Allist Pharmaceuticals Co., Ltd. focuses on the development and commercialization of Furmonertinib. These alliances not only bolster the company’s operational strengths but also extend its impact on the global cancer treatment arena.
Contact Information
